High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial

Celine Callens, Marc Debled, Marc Delord, Isabelle Turbiez-Stalain, Corinne Veyret, Ivan Bieche, Etienne Brain

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
Original languageEnglish
Pages (from-to)383-389
JournalBreast Cancer Research and Treatment
Volume153
Issue number2
DOIs
Publication statusPublished - Sept 2015

Keywords

  • Pharmacogenetics
  • SLCO1A2
  • Febrile neutropenia
  • Docetaxel
  • Breast cancer

Cite this